Kinetic stabilization of an oligomeric protein by a single ligand binding event

被引:87
作者
Wiseman, RL
Johnson, SM
Kelker, MS
Foss, T
Wilson, IA
Kelly, JW
机构
[1] Scripps Res Inst, Dept Chem, Dept Biol Mol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1021/ja042929f
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Protein native state stabilization imposed by small molecule binding is an attractive strategy to prevent the misfolding and misassembly processes associated with amyloid diseases. Transthyretin (TTR) amyloidogenesis requires rate-limiting tetramer dissociation before misassembly of a partially denatured monomer ensues. Selective stabilization of the native TTR tetramer over the dissociative transition state by small molecule binding to both thyroxine binding sites raises the kinetic barrier of tetramer dissociation, preventing amyloidogenesis. Assessing the amyloidogenicity of a TTR tetramer having only one amyloidogenesis inhibitor (1) bound is challenging because the two small molecule binding constants are generally not distinct enough to allow for the exclusive formation of (TTRI)-I-. in solution to the exclusion of (TTRI2)-I-. and unliganded TTR. Herein, we report a method to tether one fibril formation inhibitor to TTR by disulfide bond formation. Occupancy of only one of the two thyroxine binding sites is sufficient to inhibit tetramer dissociation in 6.0 M urea and amyloidogenesis under acidic conditions by imposing kinetic stabilization on the entire tetramer. The sufficiency of single occupancy for stabilizing the native state of TTR provides the incentive to search for compounds displaying striking negative binding cooperativity (e.g., K-d1 in nanomolar range and K-d2 in the micromolar to millimolar range), enabling lower doses of inhibitor to be employed in the clinic, mitigating potential side effects.
引用
收藏
页码:5540 / 5551
页数:12
相关论文
共 58 条
[51]   Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease [J].
Volles, MJ ;
Lansbury, PT .
BIOCHEMISTRY, 2003, 42 (26) :7871-7878
[52]   WHAT IF - A MOLECULAR MODELING AND DRUG DESIGN PROGRAM [J].
VRIEND, G .
JOURNAL OF MOLECULAR GRAPHICS, 1990, 8 (01) :52-&
[53]   Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo [J].
Walsh, DM ;
Klyubin, I ;
Fadeeva, JV ;
Cullen, WK ;
Anwyl, R ;
Wolfe, MS ;
Rowan, MJ ;
Selkoe, DJ .
NATURE, 2002, 416 (6880) :535-539
[54]   FIBRIL IN SENILE SYSTEMIC AMYLOIDOSIS IS DERIVED FROM NORMAL TRANSTHYRETIN [J].
WESTERMARK, P ;
SLETTEN, K ;
JOHANSSON, B ;
CORNWELL, GG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2843-2845
[55]   Monoclonal antibodies inhibit prion replication and delay the development of prion disease [J].
White, AR ;
Enever, P ;
Tayebi, M ;
Mushens, R ;
Linehan, J ;
Brandner, S ;
Anstee, D ;
Collinge, J ;
Hawke, S .
NATURE, 2003, 422 (6927) :80-83
[56]   Use of TLS parameters to model anisotropic displacements in macromolecular refinement [J].
Winn, MD ;
Isupov, MN ;
Murshudov, GN .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2001, 57 :122-133
[57]  
Wolfe Michael S., 2002, Current Topics in Medicinal Chemistry, V2, P371, DOI 10.2174/1568026024607535
[58]   Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions [J].
Zhang, QH ;
Kelly, JW .
BIOCHEMISTRY, 2003, 42 (29) :8756-8761